Quantcast

Latest advanced prostate cancer Stories

2010-09-15 15:06:00

DETROIT, Sept. 15 /PRNewswire-USNewswire/ -- The Barbara Ann Karmanos Cancer Center in Detroit was recently selected to be one of 50 sites in the United States to offer the new U.S. Food and Drug Administration (FDA)-approved drug PROVENGE® (sipuleucel-T) to treat patients with advanced metastatic prostate cancer. (Logo: http://photos.prnewswire.com/prnh/20071106/KARMANOSLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSLOGO) PROVENGE, manufactured by...

2010-09-01 05:00:00

HORSHAM, Pa., Sept. 1 /PRNewswire/ -- World-renowned golf champion and prostate cancer survivor Arnold Palmer has teamed up with Centocor Ortho Biotech Inc. and the non-profit organization Us TOO International Prostate Cancer Education & Support Network to launch My Prostate Cancer Roadmap (www.myprostatecancerroadmap.com), an educational program that provides resources and information specific to advanced prostate cancer patients and those who love them. To view the multimedia assets...

2010-08-16 11:17:00

PARSIPPANY, N.J., Aug. 16 /PRNewswire/ -- Ferring Pharmaceuticals Inc., the makers of FIRMAGON® (degarelix for injection), is in the race to end prostate cancer as an official sponsor of the Great Prostate Cancer Challenge / Dash for Dad, the premier prostate cancer race series in the United States, led by ZERO - The Project to End Prostate Cancer. FIRMAGON® is a hormone antagonist therapy for advanced prostate cancer. "ZERO's Dash for Dad exemplifies...

2010-06-05 07:09:00

THOUSAND OAKS, Calif., June 5 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial which compared the efficacy and safety of denosumab versus Zometa® (zoledronic acid) in 1,901 patients with hormone-refractory prostate cancer and bone metastases. The study met its primary and secondary endpoints and demonstrated denosumab's superiority over Zometa in delaying or preventing skeletal related events (SREs). These...

2010-04-29 16:08:00

WASHINGTON, April 29 /PRNewswire-USNewswire/ -- Today is an exciting day for men with advanced prostate cancer and the millions of families and loved ones who are profoundly affected. Today a new prostate cancer treatment option, Provenge, was approved by the Food and Drug Administration (FDA). Men's Health Network (MHN) is excited to see this innovative treatment option made available for patients with asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone...

2010-04-29 12:08:00

SILVER SPRING, Md., April 29 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Provenge (sipuleucel-T), a new therapy for certain men with advanced prostate cancer that uses their own immune system to fight the disease. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) Provenge is indicated for the treatment of asymptomatic or minimally symptomatic prostate cancer that has spread to other parts of the body and is resistant to standard hormone...

2010-04-15 08:25:10

An experimental drug is showing promise for the treatment of men with an aggressive form of advanced prostate cancer. A new multicenter study has concluded that the targeted therapy MDV3100 is safe and effective for patients with castration-resistant prostate cancer (CRPC), known for its poor prognosis and limited treatment options. The research, led by investigators at Memorial Sloan-Kettering Cancer Center, appears early online and in an upcoming edition of The Lancet. According to the...

2010-03-11 15:15:00

MORRISTOWN, N.J., March 11 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced the U.S. Food and Drug Administration (FDA) approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer. With an anticipated May launch, TRELSTAR® 22.5 mg is the first and only...

2010-03-11 14:08:00

ABBOTT PARK, Ill., March 11 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental new drug application (sNDA) of a new six-month 45-mg formulation of Lupron®( ) Depot (leuprolide acetate for depot suspension) for use in the palliative treatment of advanced prostate cancer. Palliative treatment helps to relieve symptoms associated with advanced prostate cancer. Lupron Depot works by suppressing the production of the...

2009-09-24 10:00:00

SEATTLE and NEW YORK, Sept. 24 /PRNewswire-FirstCall/ -- At its analyst event today, Dendreon Corporation (Nasdaq: DNDN) provided updates on its regulatory and commercialization progress for PROVENGE(R) (sipuleucel-T), the Company's investigational product candidate for men with advanced prostate cancer. "2009 has been a transformational year for the company as we prepare to commercialize PROVENGE by the middle of next year and make it available to the many men with metastatic...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related